Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

Yucai Wang, Grzegorz S Nowakowski, Michael L. Wang, Stephen Maxted Ansell

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ongoing studies are evaluating their efficacy in earlier lines of therapy and have demonstrated encouraging results. These agents are expected to further change the landscape of cHL management. Increased cure rates and reduced long-term toxicity from traditional chemotherapy and radiotherapy are likely with the emergence of these novel targeted therapies.

Original languageEnglish (US)
Article number57
JournalJournal of Hematology and Oncology
Volume11
Issue number1
DOIs
StatePublished - Apr 23 2018

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this